Literature DB >> 27439388

Mission critical: the need for proteomics in the era of next-generation sequencing and precision medicine.

Devon M Cayer1, Kristopher L Nazor1, Nicholas J Schork2.   

Abstract

Next generation sequencing (NGS) has ignited an unprecedented pace of discovery in the biomedical sciences that is fundamentally transforming the way that we understand, diagnose and treat disease, and has motivated the belief that true precision medicine - medicine that is tailored to an individual's genetic, biochemical and exposure profile - will be a reality in the near term. With minimal sample requirement, NGS can enable the concurrent genome-wide study of genetic variations, transcriptomes, and certain epigenetic modifications. However, interrogating proteins as efficiently as DNA and RNA can be interrogated with NGS is lacking and this hampers more comprehensive views of molecular physiology and limits advances in biomedical science and precision medicine. The fact is that innovations in proteomic technologies pale in comparison to the advances in NGS, with current methodologies suffering from issues related to reproducibility, sensitivity, sample requirements, and limited multiplexing capacity. The development of proteomic technologies to overcome these limitations would fill the void in systems biology research, catalyze clinical innovations, and expedite the realization of precision medicine.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Year:  2016        PMID: 27439388     DOI: 10.1093/hmg/ddw214

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  7 in total

1.  Multiplexed ion beam imaging analysis for quantitation of protein expression in cancer tissue sections.

Authors:  Sandra Rost; Jennifer Giltnane; Jennifer M Bordeaux; Chuck Hitzman; Hartmut Koeppen; Scot D Liu
Journal:  Lab Invest       Date:  2017-05-29       Impact factor: 5.662

Review 2.  Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome.

Authors:  Lois Gardner; Kostas Kostarelos; Parag Mallick; Caroline Dive; Marilena Hadjidemetriou
Journal:  Nat Rev Clin Oncol       Date:  2022-06-23       Impact factor: 65.011

3.  Cervicovaginal fluid proteomic analysis to identify potential biomarkers for preterm birth.

Authors:  Samuel Parry; Rita Leite; M Sean Esplin; Radek Bukowski; Heping Zhang; Michael Varner; William W Andrews; George R Saade; John Ilekis; Uma M Reddy; Hao Huang; Yoel Sadovsky; Ian A Blair; Joseph Biggio
Journal:  Am J Obstet Gynecol       Date:  2019-11-20       Impact factor: 8.661

Review 4.  Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities.

Authors:  Jacques S Beckmann; Daniel Lew
Journal:  Genome Med       Date:  2016-12-19       Impact factor: 11.117

5.  Cohort profile of the PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects (PREDICTS) study: Rationale, organization, design, and baseline characteristics.

Authors:  Chad K Porter; Mark S Riddle; Ramiro L Gutierrez; Fred Princen; Rick Strauss; Shannon E Telesco; Joana Torres; Rok Seon Choung; Renee M Laird; Francisco Leon; Jean-Frédéric Colombel; Joseph A Murray
Journal:  Contemp Clin Trials Commun       Date:  2019-03-26

6.  Quantitative Analysis of the Seminal Plasma Proteome in Secondary Hypogonadism.

Authors:  Giuseppe Grande; Federica Vincenzoni; Francesca Mancini; Ferran Barrachina; Antonella Giampietro; Massimo Castagnola; Andrea Urbani; Rafael Oliva; Domenico Milardi; Alfredo Pontecorvi
Journal:  J Clin Med       Date:  2019-12-03       Impact factor: 4.241

7.  Calretinin is a novel candidate marker for adverse ovarian effects of early life exposure to mixtures of endocrine disruptors in the rat.

Authors:  Hanna Katarina Lilith Johansson; Terje Svingen; Julie Boberg; Paul A Fowler; David Stead; Anne Marie Vinggaard; Panagiotis Filis
Journal:  Arch Toxicol       Date:  2020-03-27       Impact factor: 5.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.